[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362596-105":59,"doc-detail-362596-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","real-world-external-control-arm-for-the-single-arm-libretto-001-trial-of-selpercatinib-in-ret-mutation-positive-medullary-thyroid-cancer-recalib-ret","Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET","","Real-world external control arm evidence was generated for the single-arm phase I/II LIBRETTO-001 study of selpercatinib in RET-mutation-positive medullary thyroid cancer. RECALIB-RET compared real-world external control patients treated with standard of care against selpercatinib outcomes, using propensity score matching to balance baseline characteristics. In treatment-naïve (1L) patients, selpercatinib showed statistically significant progression-free survival benefit pre- and post-matching. In later-line (≥2L) patients, median PFS favored selpercatinib pre-matching, with inconclusive results after matching; safety aligned with prior SoC reports.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-external-control-arm-for-the-single-arm-libretto-001-trial-of-selpercatinib-in-ret-mutation-positive-medullary-thyroid-cancer-recalib-ret/362596/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-external-control-arm-for-the-single-arm-libretto-001-trial-of-selpercatinib-in-ret-mutation-positive-medullary-thyroid-cancer-recalib-ret/362596.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"How was the real-world external control (EC) arm constructed in RECALIB-RET?","Question",{"text":112,"@type":113},"The EC arm included standard-of-care patients pooled from the French ENDOCANTUTHYREF database, a European chart review, and a published United States chart review, covering first-line and later-line groups as specified.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What endpoint was used to evaluate effectiveness?",{"text":117,"@type":113},"Progression-free survival (PFS) was the primary endpoint.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find for treatment-naïve (1L) patients?",{"text":121,"@type":113},"In 1L patients, selpercatinib produced statistically significant PFS benefit versus standard of care both before and after propensity score matching.",{"name":123,"@type":110,"acceptedAnswer":124},"Were the results consistent in later-line (≥2L) patients?",{"text":125,"@type":113},"Later-line results showed a significant PFS advantage before matching, but the difference did not reach significance after propensity score matching, leading to inconclusive findings in that setting.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},362596,1790260982,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","ORIGINAL ARTICLE  \nReal-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET  \nJ. Hadoux1 , 2, J. Hernando3, K. H. Wong4, C. Do Cao2 , 5, H. Lasolle2 , 6, C. Buffet2 , 7, D. Benisvy2 , 8, F. Illouz2 , 9, O. Schneegans2 , 10, R. Varnier2 , 11, 12, D. Drui2 , 13, S. Zanetta2 , 14, S. Hescot2 , 15, M. Muller2 , 16, C. Nascimento2 , 17,  \nN. Roudaut2 , 18, M. Khanal19, S. Zheng20, X. Li5 , 19, R. Singh19, W. Tian19, A. S. Afonso19, B. Houot1 , 2, I. Borget2 , 21 , 22 &  \nG. Segall19 ∗  \n1Service d’Oncologie Endocrinienne, Département d’Imagerie, Gustave Roussy, Université Paris Saclay, Villejuif; 2ENDOCAN-TUTHYREF Network, France; 3Department of Medical Oncology, Hepatobiliary Pancreatic Cancer and Endocrine Tumors Unit, Neuroendocrine and Endocrine Tumor Translational Research Program (NETVHIO), Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; 4Head and Neck, and Thyroid Units, The Royal Marsden NHS Foundation Trust, Sutton, UK; 5CHU de Lille, Department of Endocrinology and Metabolism, Lille; 6Fédération d’Endocrinologie, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron; 7Thyroid Disease and Endocrine Tumor Department, Pitié-Salpêtrière Hospital, APHP, Sorbonne-University, University Cancer Institute, Paris; 8Département de médecine nucléaire, Centre Antoine Lacassagne, Nice; 9Department of Endocrinology, Angers University Hospital, Angers; 10ICANS: Institut de Cancérologie de Strasbourg Europe, Strasbourg Cedex; 11Département de Cancérologie Médicale, Centre Léon Bérard, Lyon; 12U1290 Research on Healthcare Performance (RESHAPE), Université Claude Bernard Lyon 1, INSERM, Lyon; 13Nantes Université, CHU Nantes, Service Endocrinologie Diabétologie et Nutrition, l’Institut du Thorax, Nantes; 14Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Medical Oncology, Dijon; 15Institut Curie, Service de Médecine Nucléaire, Saint-Cloud; 16Endocrinology Unit, CHU Grenoble Alpes, CS10217, Grenoble; 17Nuclear Medicine Department, Institut Universitaire du Cancer Toulouse - Oncopole Claudius Regaud, Toulouse; 18Department of Endocrinology, University Hospital of Brest, Brest, France; 19Eli Lilly and Company, Indianapolis; 20TechData Service Company LLC, King of Prussia, USA; 21Biostatistics and Epidemiology Office, Clinical Research Division, Gustave Roussy, Paris-Saclay University, Villejuif; 22CESP U1018, Oncostat, Labeled Ligue Contre le Cancer, Inserm, Université Paris-Saclay, Villejuif, France  \nAvailable online xxx  \nBackground: The single-arm phase I/II LIBRETTO-001 trial demonstrated durable efficacy with selpercatinib in patients with rearranged during transfection (RET)-mutation-positive medullary thyroid cancer (MTC) . RECALIB-RET compared effectiveness outcomes using a real-world external control (EC) arm of patients with RET-mutation-positive MTC treated with standard of care (SoC) versus selpercatinib (LIBRETTO-001) .  \nPatients and methods: In this retrospective study, the selpercatinib arm comprised first-line (1L) or second-and-later-line (≥2L) patients from LIBRETTO-001 . The EC arm comprised SoC-treated patients, pooled across (i) the French ENDOCANTUTHYREF (Refractory Thyroid Tumours) database (1L and ≥2L); (ii) a chart review of European patient medical records (1L and ≥2L) and (iii) a published United States chart review (≥2L) . Index treatment was cabozantinib or vandetanib (1L) and any SoC (≥2L; including multikinase inhibitor, chemotherapy or immunotherapy) . The primary endpoint was progression-free survival (PFS) . The safety profile of SoC in the EC arm was a secondary endpoint. Propensity score matching (PSM) balanced baseline characteristics between treatment arms.  \nResults: Baseline characteristics of the 1L selpercatinib (n = 116) and EC (n = 107) arms were balanced; PSM reduced the sample size by \u003C30% across arms (n = 84 per arm after PSM) . ","cbCaihMCTY0008KP","https://ap.wps.com/l/cbCaihMCTY0008KP","pdf",1530878,15,"English","# Introduction\n# Background\n# Patients and methods\n## Study design and external control arm construction\n## Endpoints and statistical approach\n# Results\n## Baseline balance and progression-free survival\n## Later-line subgroup findings\n# Safety\n# Conclusion","[{\"question\":\"How was the real-world external control (EC) arm constructed in RECALIB-RET?\",\"answer\":\"The EC arm included standard-of-care patients pooled from the French ENDOCANTUTHYREF database, a European chart review, and a published United States chart review, covering first-line and later-line groups as specified.\"},{\"question\":\"What endpoint was used to evaluate effectiveness?\",\"answer\":\"Progression-free survival (PFS) was the primary endpoint.\"},{\"question\":\"What did the study find for treatment-naïve (1L) patients?\",\"answer\":\"In 1L patients, selpercatinib produced statistically significant PFS benefit versus standard of care both before and after propensity score matching.\"},{\"question\":\"Were the results consistent in later-line (≥2L) patients?\",\"answer\":\"Later-line results showed a significant PFS advantage before matching, but the difference did not reach significance after propensity score matching, leading to inconclusive findings in that setting.\"}]","Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET | PDF",1790148497,38,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b4f46fde2bd2c9c48808fc42ac27021.webp",983,1269,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5949fc3c9651f129e5ec99702a146c22.webp",982,1268,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c7bf2a9d5fa7bfd2cfe9291099bfd705.webp",981,1266,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/264cb8ed306172a2ea4720b1c41bc5e7.webp",980,1265]